Edesa Biotech reports FY2022 net loss $17.55M; cash $7.09M; Phase 2 COVID ARDS positive

Edesa Biotech, Inc.

Net loss of $17.55M ($1.05 loss per share) vs $13.34M ($1.10) in FY2021.
Total operating expenses decreased 22% to $18.37M from $23.68M year-over-year.
Cash and equivalents $7.09M at Sept 30, 2022; subsequent private placement raised ~$3.0M.
Phase 2 study of EB05 in COVID ARDS showed 84% reduction in risk of death vs placebo at 28 days.
Phase 2b dermatology study fully enrolled; topline data expected within 4 weeks.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Edesa Biotech, Inc. reported fiscal year ended September 30, 2022 results: net income $17.55 million, or $1.05 per common share, EPS $1.05 per common share.

Period: fiscal year ended September 30, 2022
Net income: $17.55 million, or $1.05 per common share
EPS: $1.05 per common share
Result: reported results

Exact text from the filing

For the fiscal year ended September 30, 2022, Edesa reported a net loss of $17.55 million, or $1.05 per common share, compared to a net loss of $13.34 million, or $1.10 per common share, for the fiscal year ended September 30, 2021.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Edesa Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-22-016606

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.